DOC Pharma strengthens its offerings with the acquisition of the Geopharma nutraceuticals portfolio, and the closing of the previously announced acquisition of Muscoril® New brand identity ...

RBC Capital analyst Luca Issi maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) yesterday and set a price target of $77.00. The company’s shares closed yesterday at ...

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $284.00. The company’s shares closed yesterday at $264.89.

Nvidia exited its positions in several AI stocks in Q4, but maintained its stake in Recursion Pharmaceuticals. Many investors seemed to view this as a vote of confidence from Nvidia for Recursion.

As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.

The Company had approximately $98.8 million in cash and cash equivalents as of December 31, 2024. Net cash used in operating activities was approximately $60.9 million, compared to $102.0 million ...

The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. pharmaphorum looks at its evolution over the centuries. The roots of the ...

The mouse on the right with four times the normal muscle mass is placed with a normal mouse. Handout via REUTERS About a dozen drugmakers are developing new weight-loss treatments aimed at ...

On Tuesday, Recursion Pharmaceuticals stock reached a key performance benchmark, with its Relative Strength (RS) Rating rising into the 90-plus percentile with an improvement to 92, a rise from 64 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Johnson & Johnson said on Friday it resumed the limited market release of its Varipulse heart device in the United States after an investigation found the devices operate as intended. J&J resumes ...

Sanofi S.A. Part Cert 0.02% €8.03M ...